CMV infection following nonmyeloablative allogeneic stem cell transplantation using Campath

We would like to comment on the recent report by Chakrabarti et al[1][1] on the risk of cytomegalovirus (CMV) infection following nonmyeloablative allogeneic transplantation. The conditioning regimen utilized by the authors consisted of fludarabine, melphalan, and a total dose of 100 mg of